- Home
- CKPT vs AEYE Comparison
CKPT vs AEYE Comparison
Compare CKPT & AEYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CKPT
- AEYE
- Stock Information
- Founded
- CKPT 2014
- AEYE 2005
- Country
- CKPT United States
- AEYE United States
- Employees
- CKPT N/A
- AEYE N/A
- Industry
- CKPT Biotechnology: Pharmaceutical Preparations
- AEYE Computer Software: Prepackaged Software
- Sector
- CKPT Health Care
- AEYE Technology
- Exchange
- CKPT Nasdaq
- AEYE Nasdaq
- Market Cap
- CKPT 172.4M
- AEYE 205.3M
- IPO Year
- CKPT 2017
- AEYE N/A
- Fundamental
- Price
- CKPT $3.13
- AEYE $15.21
- Analyst Decision
- CKPT Strong Buy
- AEYE Strong Buy
- Analyst Count
- CKPT 3
- AEYE 5
- Target Price
- CKPT $12.00
- AEYE $29.10
- AVG Volume (30 Days)
- CKPT 753.4K
- AEYE 141.9K
- Earning Date
- CKPT 03-21-2025
- AEYE 03-05-2025
- Dividend Yield
- CKPT N/A
- AEYE N/A
- EPS Growth
- CKPT N/A
- AEYE N/A
- EPS
- CKPT N/A
- AEYE N/A
- Revenue
- CKPT $47,000.00
- AEYE $33,348,000.00
- Revenue This Year
- CKPT N/A
- AEYE $14.66
- Revenue Next Year
- CKPT $300,658.78
- AEYE $21.01
- P/E Ratio
- CKPT N/A
- AEYE N/A
- Revenue Growth
- CKPT N/A
- AEYE 6.94
- 52 Week Low
- CKPT $1.38
- AEYE $5.89
- 52 Week High
- CKPT $4.50
- AEYE $34.85
- Technical
- Relative Strength Index (RSI)
- CKPT 46.36
- AEYE 31.00
- Support Level
- CKPT $3.10
- AEYE $17.91
- Resistance Level
- CKPT $3.43
- AEYE $17.29
- Average True Range (ATR)
- CKPT 0.26
- AEYE 0.97
- MACD
- CKPT 0.00
- AEYE -0.39
- Stochastic Oscillator
- CKPT 33.03
- AEYE 1.83
About CKPT Checkpoint Therapeutics Inc.
Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in the USA. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its licensed portfolio of antibodies includes targeting programmed cell death-ligand 1 (PD-L1), glucocorticoid-induced TNFR-related protein (GITR) and carbonic anhydrase IX (CAIX). The company is evaluating its lead small-molecule, targeted anti-cancer agent, olafertinib, a third-generation epidermal growth factor receptor ("EGFR") inhibitor, as a potential new treatment for patients with EGFR mutation-positive non-small cell lung cancer.
About AEYE AudioEye Inc.
AudioEye Inc is a software solution provider delivering immediate ADA and WCAG accessibility compliance at scale. Through patented technology, subject matter expertise and proprietary processes, it is eradicating all barriers to digital accessibility, helping creators get accessible and supporting them with ongoing advisory and automated upkeep. Trusted by the ADP, Tommy Hilfiger, A360 Media, Samsung, Landry's, and others. It helps everyone identify and resolve issues of accessibility and enhance user experiences, automating digital accessibility for the widest audiences.